AtriCure to Announce Second Quarter 2013 Financial Results

  AtriCure to Announce Second Quarter 2013 Financial Results

Business Wire

WEST CHESTER, Ohio -- July 10, 2013

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the
development of technologies and solutions for the treatment of atrial
fibrillation, or Afib, and systems for the exclusion of the left atrial
appendage, will release its financial results for the second quarter of 2013
on Thursday, August 1, 2013.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday,
August 1, 2013 to discuss its second quarter 2013 financial results. A live
webcast of the conference call will be available online from the investor
relations page of AtriCure’s corporate website at www.atricure.com.

Pre-registration is available and recommended for this call at the following
URL:
https://www.theconferencingservice.com/prereg/key.process?key=P8UMYGL37

You may also access this call through an operator by calling (888) 713-4211
for domestic callers and (617) 213-4864 for international callers at least 15
minutes prior to the call start time using reservation code 51971753.

The webcast will be available on AtriCure’s website and a telephonic replay of
the call will also be available through September 1, 2013. The replay dial-in
numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for
international callers. The reservation code is 22164965.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative Atrial
Fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of Atrial Fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Contact:

AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
awade@atricure.com
OR
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com